News | August 26, 2024
Akums Q1 FY25 revenue up 5.1%
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
This transaction is the third acquisition by three different Japanese players in this segment
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Himanshu brings with him a wealth of rich experience from commercial, marketing, and general management roles
The Issue opened on June 18, 2024 and closed on June 21, 2024
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Subscribe To Our Newsletter & Stay Updated
